The estimated Net Worth of Kim Smith Whitley is at least $1.11 Milion dollars as of 1 September 2022. Dr Whitley owns over 2,208 units of Global Blood Therapeutics stock worth over $451,212 and over the last 3 years he sold GBT stock worth over $0. In addition, he makes $654,000 as Exec. VP and Head of R&D at Global Blood Therapeutics.
Dr has made over 2 trades of the Global Blood Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 2,208 units of GBT stock worth $151,226 on 1 September 2022.
The largest trade he's ever made was exercising 6,040 units of Global Blood Therapeutics stock on 1 June 2022 worth over $413,680. On average, Dr trades about 1,650 units every 18 days since 2021. As of 1 September 2022 he still owns at least 6,588 units of Global Blood Therapeutics stock.
You can see the complete history of Dr Whitley stock trades at the bottom of the page.
Dr. Kim Smith-Whitley M.D. is the Exec. VP and Head of R&D at Global Blood Therapeutics.
As the Exec. VP and Head of R&D of Global Blood Therapeutics, the total compensation of Dr D at Global Blood Therapeutics is $654,000. There are 11 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.
Dr D is 60, he's been the Exec. VP and Head of R&D of Global Blood Therapeutics since . There are 10 older and 10 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.
Kim's mailing address filed with the SEC is C/O GLOBAL BLOOD THERAPEUTICS, INC., 181 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... oraz Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Global Blood Therapeutics executives and other stock owners filed with the SEC include: